Mindray, a medical devices and solutions company based in China, has launched cardiac biomarkers of troponin I (hs-cTnI) and NT- high sensitivity proBNP. These launches enrich Mindray's diverse portfolio of cardiac biomarkers for the diagnosis and management of cardiovascular diseases (CVDs).
The guidelines recommend the use of cTnl and NT-proBNP as essential biomarkers in suspected acute coronary syndrome (ACS) and heart failure in scenarios of early screening, risk stratification, rapid diagnosis and therapeutic monitoring.
The two tests are the result of collaboration between Mindray and HyTest, a Mindray subsidiary that is also a leading global supplier of antibodies and antigens. Cardiac Troponin Complex from HyTest - a company known for its expertise in the cardiac biomarker industry - was selected as an international troponin standard by the American Association for Clinical Chemistry (AACC) in 2004.
Validated by the Wuhan Asian Cardiac Hospital (China) and the Hennepin Healthcare Research Institute (USA), the two tests show excellent clinical performance.
